NASDAQ:CUE - Cue Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.46 +0.35 (+5.73 %)
(As of 02/18/2019 04:00 PM ET)
Previous Close$6.11
Today's Range$6.12 - $6.58
52-Week Range$4.16 - $17.99
Volume71,568 shs
Average Volume82,525 shs
Market Capitalization$133.70 million
P/E RatioN/A
Dividend YieldN/A
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers and autoimmune disorders. The company's lead drug candidate includes CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to human papilloma virus related cancers. Its biologics drug candidates also comprise CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. The company also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. Cue Biopharma, Inc. has collaboration agreements with Merck & Co. for the research and development of its proprietary biologics that target autoimmune disease indications; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. It also has a strategic collaboration with LG Chem Life Sciences for Immuno- STATs biologics in oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts.

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CUE



Sales & Book Value

Annual SalesN/A
Book Value$3.17 per share


Net Income$-23,230,000.00


Market Cap$133.70 million
OptionableNot Optionable

Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) posted its earnings results on Monday, May, 14th. The company reported ($0.37) earnings per share for the quarter. View Cue Biopharma's Earnings History.

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Cue Biopharma.

What price target have analysts set for CUE?

1 brokers have issued twelve-month price targets for Cue Biopharma's shares. Their predictions range from $14.50 to $14.50. On average, they expect Cue Biopharma's share price to reach $14.50 in the next year. This suggests a possible upside of 124.5% from the stock's current price. View Analyst Price Targets for Cue Biopharma.

What is the consensus analysts' recommendation for Cue Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cue Biopharma.

Has Cue Biopharma been receiving favorable news coverage?

News articles about CUE stock have trended positive recently, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cue Biopharma earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of Cue Biopharma's key competitors?

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the folowing people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 58)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 62)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 43)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 46)
  • Dr. Steven C. Almo, Founder and Chairman of Scientific & Clinical Advisory Board (Age 58)

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.36%), Nantahala Capital Management LLC (4.24%), Geode Capital Management LLC (0.63%), Bank of New York Mellon Corp (0.25%), Sphera Funds Management LTD. (0.24%) and Rhumbline Advisers (0.11%). Company insiders that own Cue Biopharma stock include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Daniel R Passeri and Kerri-Ann Millar. View Institutional Ownership Trends for Cue Biopharma.

Which institutional investors are selling Cue Biopharma stock?

CUE stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc. and BlackRock Inc.. View Insider Buying and Selling for Cue Biopharma.

Which institutional investors are buying Cue Biopharma stock?

CUE stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Nantahala Capital Management LLC, Geode Capital Management LLC, Rhumbline Advisers and Bank of New York Mellon Corp. Company insiders that have bought Cue Biopharma stock in the last two years include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Daniel R Passeri and Kerri-Ann Millar. View Insider Buying and Selling for Cue Biopharma.

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $6.46.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $133.70 million. Cue Biopharma employs 30 workers across the globe.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 781-305-7777.

MarketBeat Community Rating for Cue Biopharma (NASDAQ CUE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Cue Biopharma and other stocks. Vote "Outperform" if you believe CUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel